alzheon, Author at Alzheon | Preserving Future Memories - Page 7 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 205 blog entries.

7 Jun, 2022

Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference

alzheon2024-08-12T09:18:21-04:00June 7th, 2022|

14 Apr, 2022

Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio

alzheon2024-08-26T10:54:53-04:00April 14th, 2022|

14 Apr, 2022

Alzheimer’s Drug Developer Alzheon Secures $50 Million

alzheon2023-05-01T08:55:43-04:00April 14th, 2022|Tags: WSJ|

14 Apr, 2022

Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance

alzheon2024-08-26T10:49:27-04:00April 14th, 2022|

8 Mar, 2022

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

alzheon2024-08-12T09:23:49-04:00March 8th, 2022|

8 Feb, 2022

Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

alzheon2024-08-12T09:05:12-04:00February 8th, 2022|

5 Jan, 2022

Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022

alzheon2024-08-12T09:33:43-04:00January 5th, 2022|

1 Jan, 2022

Anti-Amyloid Drugs: The Failure Of Success

alzheon2022-01-04T13:37:06-05:00January 1st, 2022|

9 Nov, 2021

Big Pharma Abandoned Alzheimer’s, This Good Unicorn Stayed And Found A Potential Cure

alzheon2021-11-09T18:42:03-05:00November 9th, 2021|

1 Nov, 2021

Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference

alzheon2024-08-12T10:06:16-04:00November 1st, 2021|Tags: Press Release Tag|